What is HC Wainwright’s Forecast for LVTX Q1 Earnings?

LAVA Therapeutics (NASDAQ:LVTX) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of LAVA Therapeutics in a research note issued on Monday, March 31st. HC Wainwright analyst A. He anticipates that the company will earn ($0.40) per share for the quarter. HC Wainwright has a “Neutral” rating and a $1.50 price target on the stock. The consensus estimate for LAVA Therapeutics’ current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for LAVA Therapeutics’ FY2025 earnings at ($1.46) EPS, FY2026 earnings at ($0.79) EPS, FY2027 earnings at ($0.40) EPS, FY2028 earnings at ($0.39) EPS and FY2029 earnings at ($0.40) EPS.

LAVA Therapeutics (NASDAQ:LVTX) last announced its earnings results on Friday, March 28th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.18. The firm had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $2.40 million.

A number of other brokerages also recently commented on LVTX. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a research report on Thursday, December 12th. Citizens Jmp lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Leerink Partnrs cut LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, JMP Securities restated a “market perform” rating and set a $6.00 price target on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $3.17.

LAVA Therapeutics Stock Performance

NASDAQ:LVTX opened at $1.16 on Thursday. LAVA Therapeutics has a 52 week low of $0.85 and a 52 week high of $3.57. The firm has a 50-day moving average price of $1.15 and a two-hundred day moving average price of $1.36. The firm has a market cap of $30.50 million, a price-to-earnings ratio of -1.13 and a beta of 0.48.

Hedge Funds Weigh In On LAVA Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new position in shares of LAVA Therapeutics in the third quarter valued at $32,000. BNP Paribas Financial Markets purchased a new position in LAVA Therapeutics during the 4th quarter valued at about $40,000. Finally, Sanofi bought a new stake in shares of LAVA Therapeutics during the fourth quarter valued at about $1,825,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.